Bayer — asundexian
for Secondary prevention after non-cardioembolic ischemic stroke or TIA
Accepted MAY 18 2026.
for Secondary prevention after non-cardioembolic ischemic stroke or TIA
Accepted MAY 18 2026.
A stroke happens when blood flow to part of the brain is cut off, causing brain cells to die; most strokes are ischemic, meaning a clot blocks an artery in the brain, and a transient ischemic attack (TIA) is a brief, clot-related warning episode that often signals a full stroke is coming. Asundexian is an oral drug that blocks Factor XIa, a clotting protein involved in forming the clots that cause these blockages. Because it targets that clotting step, asundexian may help prevent a second stroke or TIA in people who have already had one.
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: * an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or * TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a b...
Source: ClinicalTrials.gov